RCT | Effect of Nintedanib on progression of systemic sclerosis-associated interstitial lung disease over 100 weeks.
21 Jul, 2022 | 13:03h | UTCCommentary: Durable Efficacy for Drug Preventing Lung Progression in Systemic Sclerosis — One-year results sustained over another 48 weeks – MedPage Today (free registration required)